Concord Biotech Limited IPO
Concord Biotech Limited was a mainboard IPO in the Pharmaceuticals sector, offered at ₹705–₹741 per share to raise ₹1,551 crore. The issue was subscribed 24.87× overall (QIBs 67.67×, NIIs 16.99×, retail 3.78×). It listed on 18 Aug 2023 at ₹900 and closed its first day at ₹943, a listing gain of +27.2% versus the ₹741 issue price. It now trades around ₹1,246 (+68.1% versus the issue price).
Frequently asked questions
- How many times was the Concord Biotech Limited IPO subscribed?
- The Concord Biotech Limited IPO was subscribed 24.87× overall — 67.67× in the QIB category, 16.99× among non-institutional investors, 3.78× in retail.
- What were the Concord Biotech Limited IPO listing gains?
- Concord Biotech Limited listed on 18 Aug 2023 at ₹900, closing its first day at ₹943 — a listing gain of +27.2% versus the ₹741 issue price.
- What were the retail allotment odds for the Concord Biotech Limited IPO?
- Retail was subscribed 3.84×, so a single-lot application had roughly a 26% chance of allotment (about 1 in 4), and allotment was finalised on 14 Aug 2023.
- What was the price band and lot size of the Concord Biotech Limited IPO?
- The price band was ₹705–₹741 per share, with a minimum lot of 20 shares (₹14,820 at the upper band).
- Who were the registrar and lead manager for the Concord Biotech Limited IPO?
- Link Intime India Private Limited was the registrar, and Kotak Mahindra Capital was the book-running lead manager.